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Summary
We show that a membrane-associated protease, aminopeptidase A (APA), is upregulated and enzymatically active in blood
vessels of human tumors. To gain mechanistic insight, we evaluated angiogenesis in APA null mice. We found that, although
these mice develop normally, they fail to mount the expected angiogenic response to hypoxia or growth factors. We then
isolated peptide inhibitors of APA from a peptide library and show that they specifically bind to and inhibit APA, suppress
migration and proliferation of endothelial cells, inhibit angiogenesis, and home to tumor blood vessels. Finally, we success-
fully treated tumor-bearing mice with APA binding peptides or anti-APA blocking monoclonal antibodies. These data show
that APA is a regulator of blood vessel formation, and can serve as a functional vascular target.
Introduction targeting of blood vessels in mice and more recently in humans
(Arap et al., 2002; Pasqualini and Ruoslahti, 1996). Some of the
targets in tumor blood vessels turned out to be membrane-The realization that angiogenic vasculature is a target for inter-
vention in cancer has long led to an interest in endothelial cell bound proteinases such as matrix metalloproteinases (Koivunen
et al., 1999) or aminopeptidases (Pasqualini et al., 2000) thatreceptors associated with tumor blood vessels and their corre-
sponding ligands. However, so far, only a few such targets have are upregulated in tumor blood vessels. While the biological
relevance of the selective expression of proteinases within thebeen identified.
We developed a selection system in which circulating li- angiogenic tumor blood vessel is not entirely understood, one
can exploit such a feature to gain control of angiogenesis.gands that home to specific vascular beds in vivo are isolated
from a phage display random peptide library; this approach led Aminopeptidase A (glutamyl-aminopeptidase, EC 3.4.11.7,
APA) is a homodimeric type II membrane-spanning cell surfaceto the identification of vascular receptors allowing for systemic
S I G N I F I C A N C E
Angiogenesis is a complex multistep process that can occur in tumors or in response to various stimuli. Many lines of evidence
indicate that tumor growth and angiogenesis depend on proteolytic activity. Angiogenic blood vessels express biochemical markers
that are differentially expressed and whose functional importance has just begun to be uncovered. While only a few markers
associated with angiogenic blood vessels have thus far been reported, it is remarkable that several are cell membrane-associated
proteinases. By using genetic elimination and biochemical inhibition, our results demonstrate a novel mechanistic role for APA in
pathological angiogenesis. Thus, specific APA inhibitors—such as peptidomimetics or anti-APA antibodies—may prove useful for
translational applications targeting tumor vasculature.
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Figure 1. APA-deficient mice have an impaired angiogenesis phenotype
APA/, APA/, and APA/ mouse pups were exposed to 75% oxygen (from P7 to P12) and eyes were enucleated on P19. Paraffin sections were stained
with H&E.
A and B: A large number of new blood vessels are seen protruding from the retina into the vitreous space in wild-type (APA/) eyes (A) (arrows point to
endothelial cell nuclei), while no neovasculature is present in APA/ eyes (B). Scale bar: 50 m.
C: The number of neovascular nuclei protruding into the vitreous space was quantified by evaluating several serial sections of multiple eyes. Each circle
represents the mean of at least ten eye sections. A horizontal bar represents the mean of the group.
D and E: Gelfoam sponges impregnated with VEGF, bFGF, and TGF- were implanted in the subcutaneous tissue of APA/ and APA/ mice. Sponges
were removed 14 days later and sections were stained with anti-CD31 antibody to visualize the endothelial cells. A large number of endothelial cells (2.55
0.08 area units) are seen protruding to the sponges in APA/ mice (D) while the number of new blood vessels is smaller (0.73  0.01 area units, p  0.001)
in the sponge implanted in APA/ mice (E). Scale bar: 250 m.
protein with zinc metallopeptidase activity that hydrolyzes suppresses migration and proliferation of endothelial cells, (3)
inhibits in vitro and in vivo angiogenesis, (4) homes to tumorN-terminal glutamyl or aspartyl residues from oligopeptide sub-
strates (Nanus et al., 1993; Wu et al., 1990). Surprisingly, despite vasculature in vivo, and (5) inhibits tumor growth in vivo. These
genetic and biochemical data show that APA is a functionalwidespread tissue distribution (Li et al., 1993), APA null mice
develop normally (Lin et al., 1998). Since upregulation of APA target in tumor blood vessels.
has been reported in perivascular cells (termed “pericytes”) of
tumor blood vessels (Alliot et al., 1999; Schlingemann et al., Results
1996), we set out to identify and analyze the effects of targeted
ligands on the possible role of this enzyme in angiogenesis. APA/ mice show impaired angiogenesis
We have evaluated the angiogenic response of APA/ mice inTo evaluate whether an APA ligand-receptor system would
allow functional targeting of tumor blood vessels, we designed two models of angiogenesis. First, we used a mouse model
of O2-induced retinopathy (Smith et al., 1994). APA wild-typeexperiments to assess both partners of the protein-protein inter-
action. We show that (1) APA is strongly upregulated in angio- (APA/), APA heterozygotes (APA/), and APA null (APA/)
mice were exposed to 75% O2 from postnatal day 7 (P7) togenic tumor blood vessels but barely detectable in normal blood
vessels, (2) the enzymatic activity of APA colocalizes to its ex- P12, and then returned to room air. Retinas were analyzed at
P17, when neovascularization had supervened on the vitrealpression pattern in human tumors, and finally (3) APA null mice
have an impaired angiogenesis phenotype that has not been surface. Angiogenesis was quantified by counting endothelial
cell nuclei protruding into the vitreous space (Lahdenranta etpreviously characterized. To gain insight into the functional role
of APA in angiogenesis, we used a phage display library to al., 2001; Smith et al., 1994). Induction of retinal angiogenesis
(16.1  3.3 endothelial cell nuclei/section) was seen in wild-select APA binding peptides and to isolate a novel inhibitory
ligand. We show that the consensus motif CPRECESIC (1) spe- type mice on P17 (Figure 1A), but significantly fewer endothelial
cell nuclei (3.0  0.4 endothelial cell nuclei/section, t test, p cifically binds to APA and inhibits its enzymatic activity, (2)
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Figure 2. Selection and identification of APA
binding peptides
A: A phage peptide library was preabsorbed on
APA negative SK-RC-49 cell line and incubated
with stably APA-transfected SK-RC-49 cells. Cell-
bound phage were recovered by infection and
used for further rounds of panning on SK-RC-49/
APA cells. By the third round of selection, we
observed strong enrichment in phage binding to
APA-transfected SK-RC-49 cells. Shown are
mean  standard error of the means (SEM) from
triplicate samples.
B: Binding of the selected phage clones to SK-
RC-49 /APA cells was compared to binding to
SK-RC-49 cells. Insertless fd-tet phage was used
as a negative control. The designation tandem
refers to the peptide sequence CYNLCIRECESIC
GADGACWTWCADGCSRSC (see text). Phage
binding to the cells is shown relative to the nega-
tive control phage binding to the parental SK-
RC-49 cells (value was set to be 1). Shown are
mean  SEM from triplicate samples.
C: APA was immobilized on RC38-coated micro-
wells from SK-RC-49/APA cell lysates, and APA
enzyme activity was evaluated with the specific
substrate -glutamyl-p-nitroanilide by measuring absorbance. RC38-immobilized SK-RC-49 cell lysate showed no activity above background from the
substrate alone. Shown are mean  SEM from triplicate samples.
D: Binding of the selected phage clones to RC38-immunocaptured APA was compared to the binding to RC38-immunocaptured SK-RC-49 cell lysate. The
individual wells were then incubated with equal amounts of each individual phage. Insertless fd-tet phage was used as a negative control for the phage
binding. Phage binding to immunocaptured APA is shown relative to the negative control phage binding to immunocaptured SK-RC-49 cell lysate (value
was set to be 1). Shown are mean  SEM from triplicate samples.
0.001) were found in retinas from APA/ mice (Figure 1B). An assay specific for APA. Parental SK-RC-49 cells showed neither
intermediate decrease in retinal angiogenesis was observed in APA expression nor activity. An increase in phage binding to
the APA/ mice (10.1  2.2 endothelial cell nuclei/section), SK-RC-49/APA cells relative to SK-RC-49 cells was observed
suggesting dose dependence (Figure 1C). No endothelial cell in the third round of selection (Figure 2A). DNA sequencing
nuclei protruding into the vitreous space were found in mice revealed an enrichment of the sequence CYNLCIRECESIC-
exposed only to room air regardless of their genotype or time GADGA-CWTWCADGCSRSC containing tandem repeats of the
of analysis. general library sequence CX3CX3CX3C on each side of the pIII
As a second model, we adopted a quantitative in vivo angio- peptide linker GADGA sequence. 50% of randomly selected
genesis assay utilizing implanted gelfoam sponges saturated phage clones displayed such tandem repeat after the second
with angiogenic growth factors VEGF, bFGF, and TGF- round and 100% displayed it after the third round (Table 1).
(McCarty et al., 2002). To compare angiogenesis induction from
subcutaneous tissue, sponges were implanted into the flanks Validation of APA-specific phage ligand binding
of wild-type (APA/) or APA null mice (APA/). After two Phage displaying enriched peptide motifs were tested individu-
weeks, the sponges were harvested and stained with anti-CD31 ally for APA binding. Phage displaying the inserts CPKVCPRECE
antibodies to detect the endothelial cells of newly formed blood SNC, CYNLCIRECESICGADGACWTWCADGCSRSC, or CLGQ
vessels permeating the sponge. Strong induction of CD31-posi- CASICVNDC preferentially bound to SK-RC-49/APA cells
tive capillary structure formation was observed in the growth relative to SK-RC-49 cells; control insertless phage (fd-tet)
factor-absorbed sponges implanted into wild-type mice (Figure showed no binding preference (Figure 2B). We synthesized pep-
1D), whereas the number of CD31-positive capillary structures
was much smaller in APA/ mice and the only limited capillary
formation observed was observed at the outer surface of the
sponge (Figure 1E). Table 1. APA binding peptide sequences
These results suggest a deficient angiogenic response in Peptide sequences Round 2 (%) Round 3 (%)
APA/ mice to relative hypoxia or to angiogenic growth factors
CYNLCIRECESICGADGACWTWCADGCSRSC 50 100as compared with their otherwise isogenic APA/ counterparts.
CPKVCPRECESNC 5 
CLGQCASICVNDC 5 
Selection and identification of APA binding peptide motifs
CGTGCAVECEVVC 5 
To identify peptides capable of binding to APA, we screened CAVACWADCQLGC 5 
APA-transfected cells with a phage display library (Smith and
CSGLCTVQCLEGC 5 
Scott, 1993). We stably transfected SK-RC-49 renal carcinoma CSMMCLEGCDDWC 5 
cells with a vector expressing full-length APA cDNA. We verified
Other 20 that APA was functional in transfected cells by an enzyme activity
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tides containing APA binding motifs (consensus sequence
CPRECESIC; Table 1). Binding of phage displaying CPKVCPRE
CESNC or CYNLCIRECESICGADGACWTWCADGCSRSC pep-
tides to SK-RC-49/APA cells was specific because it was inhib-
ited by the synthetic peptide; several negative control peptides
had no inhibitory effect. Binding of CLGQCASICVNDC phage to
SK-RC-49/APA cells was not affected by the synthetic peptide,
suggesting that the SIC sequence in the consensus motif is not
critical for binding. We also evaluated whether the selected
peptides would bind to the isolated APA protein. We immuno-
captured APA from SK-RC-49/APA lysate with the RC38 anti-
body and showed that the immunocaptured APA remained en-
zymatically active (Figure 2C). We used phage displaying
CPKVCPRECESNC, CLGQCASICVNDC, or CYNLCIRECESIC
GADGACWTWCADGCSRSC in binding assays to the immuno-
captured APA. We found up to 12-fold enrichment of phage
binding to APA compared to immunocaptured cell lysates from
the SK-RC-49 cells; control insertless phage (fd-tet) showed no
binding preference (Figure 2D).
These data support the specific binding of the selected
peptides to isolated functional APA enzyme and to cell mem-
brane-bound APA in vitro.
CPRECESIC is an inhibitor of APA enzymatic activity
To evaluate the effect of synthetic CPRECESIC peptide on APA
enzyme activity, we incubated APA-transfected cells with the
APA-specific substrate -glutamyl-p-nitroanilide with increas-
ing concentrations of APA binding or control peptides. The APA
binding peptide inhibited APA enzyme activity (colorimetric
assay), while the control peptide had no effect (Figure 3A). We
calculated the IC50 of the peptide for APA enzyme inhibition to
be 800 M. The inhibition was specific to APA because the
Figure 3. CPRECESIC is a specific inhibitor of APA activity and blocks endo-
peptide did not affect the enzymatic activity of aminopeptidase thelial cell migration and proliferation
N, a related protein with homology to APA (Nanus et al., 1993; A: APA enzymatic activity in SK-RC-49/APA cells was measured in the pres-
Wu et al., 1990). ence of increasing concentrations of either targeting or control peptide.
SK-RC-49 cells served as a negative control.
B: HMECs were stimulated with complete M199 culture medium. MigrationCPRECESIC suppresses endothelial cell function
assay was performed in a Boyden microchemotaxis chamber. Cells were
Because of the enzymatic inhibitory activity of APA binding allowed to migrate through an 8 m pore filter for 5 hr at 37C in the
peptides, we reasoned that they might affect endothelial cell presence of increasing concentrations of CPRECESIC or control peptides.
Cells migrating through the membrane were stained and five high-powerfunction. We correlated the effect of APA inhibition by the
fields for each microwell were counted. Shown are means  SEM fromCPRECESIC peptide on the migration and proliferation of endo-
triplicate wells.thelial cells. We used human dermal microvascular endothelial C: HMECs were stimulated with complete M199 culture medium in the pres-
cells (HMEC) in which the APA expression was verified by immu- ence of increasing concentrations of APA binding or control peptides. Cell
proliferation was measured at 24, 48, and 72 hr by a colorimetric assaynostaining with RC38 and the APA activity by its specific enzyme
based on crystal violet staining.assay. CPRECESIC peptide suppressed the migration of
HMECs in the Boyden chamber assay (Figure 3B). Suppression
in cell migration was dose-dependent and commensurate with
inhibition of APA enzymatic activity. Up to 60% suppression in CPRECESIC inhibits capillary tube formation
cell migration was observed at 1 mM of peptide, but significant and angiogenesis
inhibition was detected at concentrations as low as 100 M To determine whether inhibition of APA enzyme activity with
(Figure 3B). Similarly, proliferation of HMECs was suppressed CPRECESIC peptide would affect angiogenesis, we tested the
by CPRECESIC (40% at 1 mM) in a dose-dependent manner effect of peptide in vitro and in vivo. First, we evaluated the
(Figure 3C). Inhibition of cell proliferation was also observed at ability of HMECs to differentiate into capillary-like structures
0.3 mM, but lower peptide concentrations had no significant characteristic of angiogenesis in the presence of CPRECESIC
effect. A negative control peptide affected neither cell migration on a gel of reconstituted basement membrane matrix (Matrigel).
nor proliferation. The formation of cord/tube-like structures was progressively
These data indicate that an APA binding peptide functions impaired by increasing concentrations of CPRECESIC peptide,
as a specific inhibitor of enzymatic activity and that inhibition relative to the network formation in controls without peptide
of APA enzymatic activity is associated with suppression of (Figure 4A, upper left panel) or with an unrelated control peptide
at 1 mM concentration (Figure 4A, upper right panel). The num-migration and proliferation in human endothelial cells in vitro.
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1.41 blood vessels) was found when a sponge with VEGF was
placed on the CAM compared to a sponge with no growth
factors (12.0 2.8 blood vessels; t test, p 0.01). CPRECESIC
peptide (1 mM) inhibited VEGF-induced CAM neovasculariza-
tion by 40% (35.5 1.4 blood vessels; t test, p 0.01). Equimo-
lar concentrations of a negative control peptide (56.5  2.12
blood vessels; t test, p  0.01, compared to the active CPECE
SIC peptide) or lower CPRECESIC peptide concentrations (0.1
mM and 0.3 mM) did not affect the number or branching of the
growing blood vessels (data not shown).
These data show that the CPRECESIC motif inhibits blood
vessel formation in standard models of angiogenesis.
APA expressed in blood vessels of human tumors
is active
The extensive proliferation of blood vessels in malignant gliomas
suggests an early role of angiogenesis in brain tumors (Wesse-
ling et al., 1995). To investigate the expression of APA in brain
tumor vasculature, we compared the localization of APA expres-
sion by immunostaining to the localization of APA activity by
enzyme histochemistry in a panel (n 14) of primary and meta-
static human brain tumors and in the incidental normal tissue
adjacent to the tumors. APA enzyme activity in tissue sections
colocalized with APA expression detected by an RC38 antibody.
The staining pattern was consistent with APA localization to
perivascular cells in the tumor microvasculature (Figures 5A
and 5B, glioblastoma multiforme; 5C and 5D, squamous cell
carcinoma of the lung metastatic to the brain). Staining and
enzymatic activity were apparent in sites of glomerular vascular
proliferation in malignant gliomas and metastatic carcinomas.
In contrast, APA expression and activity were barely detectable
in capillaries in normal brain parenchyma (data not shown). By
double staining with RC38 and with PAL-E antibody, a general
endothelial marker (Schlingemann et al., 1985), APA expression
in colon adenocarcinoma metastatic to the brain appears to be
restricted to perivascular cells (Figure 5E). We also showed
Figure 4. Inhibition of angiogenesis by CPRECESIC by immunostaining that blood vessels in human nonmalignant
A: HMECs were plated on Matrigel in the presence of increasing concentra- granulation tissue express APA (Figure 5F). Finally, we localized
tions of APA binding or control peptides and photographed after 24 hr
APA staining to perivascular cells by immuno-electron micros-(magnification: 40	).
copy (Figure 5G).B: Eight-day-old chicken egg CAMs were implanted with PBS- or VEGF-
adsorbed sponges. CPRECESIC or control peptides were tested at 1 mM These results show that the APA present in blood vessels
concentration in the VEGF-adsorbed sponge. At day 12, CAMs were evalu- during the progression of malignant tumors is enzymatically
ated and the number of neovessels quantified. There were significantly
active and therefore may contribute to the angiogenic processfewer blood vessels in the CAMs treated with APA binding peptides (*t test,
associated with human brain tumors.p  0.01). Shown are means  SEM from triplicate samples.
APA binding phage targets tumor vasculature
We next evaluated the ability of APA binding peptides to home
ber and length of capillary-like branching structures was re- to tumor blood vessels in vivo. Phage were administered intrave-
duced at 0.3 mM CPRECESIC peptide (Figure 4A, lower left nously to nude mice bearing human breast carcinoma MDA-
panel), whereas cell interconnections and the capillary network MB-435-derived xenografts. Phage homing was quantified by
organization were severely lost at a peptide concentration of 1 recovery from tissue homogenates by bacterial infection.
mM (Figure 4A, lower right panel). CPKVCPRECESNC phage were enriched in tumors compared
Next, we tested CPRECESIC activity in a CAM assay. In to control organs; in contrast, negative control phage (without
this in vivo model, neovascularization is stimulated with VEGF a peptide insert) did not enrich in tumors (Figure 6A). Homing
adsorbed on to a gelatin sponge placed on the CAM. CAMs of CPKVCPRECESNC phage to tumor vasculature was con-
were stimulated on embryonic day 8 (E8) with sponges con- firmed by immunohistochemical staining of phage on tissue
taining VEGF only, VEGF plus CPRECESIC, or VEGF plus control sections. Strong phage staining was observed in tumor blood
peptides. CAMs were examined on E12 and neovascularization vessels—but not in normal brain blood vessels—of mice that
was quantified by counting the number of emerging capillaries received CPKVCPRECESNC phage; in contrast, negative con-
trol phage without insert did not home to tumor blood vessels(Figure 4B). Significant induction of neovascularization (57.0 
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Figure 5. APA expression and activity in human brain tumor blood vessels
A–E: RC38 immunohistochemistry (A and C) and APA enzyme activity (B
and D) of an area of glomeruloid vascular proliferation in glioblastoma
multiforme (A and B) and in brain metastases from squamous cell carcinoma
of the lung (C and D). Note the similar distribution of reaction products in
both primary (A and B) and metastatic tumors (C and D), and the absence
of staining of endothelial cells lining the vascular lumina, findings consistent
with a localization of APA in the perivascular cells of these microvessels.
Scale bar: 50 m.
E: Double staining of human adenocarcinoma metastasis to the brain with
anti-APA antibody (RC38) and the antiendothelial cell antibody (PAL-E).
RC38 was detected by using DAB as the substrate producing brown staining
of perivascular cells (white arrow), and PAL-E was detected by using
4-chloro-1-naphtol as the substrate, producing blue-gray staining of endo-
thelial cells (black arrow). Note the absence of the RC38 staining in PAL-E
positive cells. Scale bar: 50 m.
F: RC38 immunohistochemistry of an area of human granulation tissue. Scale
bar: 50 m.
G: RC38 immuno-electron microscopy of an area of glomeruloid vascular
proliferation in human glioblastoma multiforme. Perivascular cells (P) are Figure 6. CPKVCPRECESNC-displaying phage targets tumor vasculature
positive for RC38 staining, whereas endothelial cells (E) are negative. Asterisk
A: The ability of the APA binding phage to home to tumors was evaluatedindicates the lumen. Scale bar: 5 m.
after intravenous administration into mice bearing human MDA-MB-435
breast carcinoma-derived tumor xenografts. Phage were recovered from
tumor and control tissues after perfusion. Shown are mean SEM of TU from
triplicate platings. Brain was used as a control tissue.
(Figure 6B). These results show that APA binding phage target B: Phage displaying the peptide CPKVCPRECESNC or insertless negative
control phage were injected intravenously into MDA-MB-435-derived tumor-tumor blood vessels in vivo.
bearing mice. An anti-phage antibody was used for staining. Arrows indi-
cate blood vessels. The upper panel shows the tumor from the mouse thatAPA binding peptides or anti-APA antibodies can received the CPKVCPRECESNC phage; the middle panel shows the brain
suppress tumor growth from the same mouse; the lower panel shows the tumor from the mouse
that received the insertless control phage. Scale bar: 70 m.To evaluate whether APA inhibitory ligands (APA binding pep-
tides or anti-APA blocking antibodies) suppress tumor growth in
vivo, we used EF43-fgf4-derived tumors, an established mouse
mammary carcinoma model (Deroanne et al., 1997, Hajitou et
ences in tumor growth as early as 5 days after treatment initia-al., 2001). We have chosen this model because APA expression
tion, and when the experiment was terminated at the end ofis undetectable in EF43-fgf4 cells but strongly induced in the
two weeks, CPRECESIC-treated mice had significantly smallertumor blood vessels associated with EF43-fgf4-derived tumors
tumors (1,366  190 mm3) relative to tumor-bearing control(Figure 7A) and homing of APA binding phage to tumor vascula-
mice that received control peptide (2,626  335 mm3; p ture was experimentally validated (data not shown). Tumor-
0.006); tumors in mice treated by control peptide behaved simi-bearing mice received vehicle, CPRECESIC, or control peptides,
and tumors were monitored (Figure 7B). We observed differ- larly to those tumors in mice receiving vehicle alone (2,295 
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Figure 7. Treatment of tumor-bearing mice with APA binding peptides or anti-APA blocking monoclonal antibodies can suppress tumor growth
A: Immunofluorescence staining of EF43-fgf4-derived tumors shows APA expression on tumor blood vessels. Frozen tumor sections were stained for CD31
and APA. CD31 was detected with a FITC-conjugated secondary antibody (green), and APA was detected with a Cy3-conjugated secondary antibody
(red); merged images indicate that APA expression is vascular and not detectable on EF43-fgf4 cells. Scale bar: 125 m (or 250 m, far right panel).
B: Balb/c mice bearing EF43-fgf4-derived tumors were divided in 3 size-matched cohorts (n  7 mice per group) that received vehicle (DMEM), CPRECESIC
peptide, or control (CARAC) peptide. Peptides were administered at 250 g/mouse/dose (indicated by arrows). Shown are mean tumor volumes  SEM.
C: Balb/c mice bearing EF43-fgf4-derived tumors were divided in 3 size-matched cohorts (n  7 mice per group) that received vehicle (DMEM), ASD-37/41
antibodies, or isotype control (rat IgG). Antibodies were administered at 200 g/mouse/dose (indicated by arrows). Shown are mean tumor volumes 
SEM.
D: After treatments (B and C) were terminated at two weeks, tumor sections were immunostained for CD31 and counterstained by hematoxylin. Representa-
tive histopathological panels are shown as indicated. Relatively to controls (far left panel), ASD-37/41-treated tumors (middle panels) contained codominant
areas of disrupted vascular structure next to islands of viable tissue (middle left panel) as well as large areas of tumor destruction with extensive cell death
(middle right panel); inhibitory peptides also had an evident effect on treated tumors (far right panel). Scale bar: 100 m.
381 mm3; p  0.53), indicating that the control peptide had monitored (Figure 7C). Again, we noticed clear differences in
tumor growth. By the end of two weeks when the experimentno measurable effect. Of note, another synthetic APA binding
peptide (sequence CPRECESN) also showed efficacy in vivo was terminated, ASD-37/41-treated mice had significantly
smaller tumor volumes (663 77 mm3) relative to tumor-bearing(data not shown).
However, because the APA-inhibitory peptides may require control mice that received isotype negative control IgG (1,442
231 mm3, p  0.013); tumors in mice treated by control IgGa relatively high molar range (250 nanomoles/mouse/dose) to
be effective, we also evaluated the effects of anti-APA antibod- behaved similarly to those tumors in mice receiving vehicle only
(1,845  313 mm3, p  0.38), indicating that control IgG hadies on tumor growth. We used an established regimen of two
anti-APA monoclonal antibodies (ASD-37/41) with synergistic no detectable effect on tumor growth. Finally, to analyze post-
treatment effects of APA-inhibitory antibodies in tumors andAPA inhibitory properties (Assmann et al., 1992, Mentzel et al.,
1999) on the same animal model. Tumor-bearing mice received their angiogenic blood vessels, we examined tissue sections of
all groups by CD31 immunostaining (Figure 7D). In contrastvehicle, ASD-37/41, or isotype control IgG, and tumors were
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to the recognized (Deroanne et al., 1997; Hajitou et al., 2001) bly due to the short sequence shared with the other isolated
peptides leading to a low-affinity interaction; this result suggestsextensive blood vessel network typically observed in EF43-fgf4-
derived tumors, ASD-37/41-treated tumors exhibited a mixture that the sequence CPRECES alone is sufficient to promote inhi-
bition. Functionally, the peptide CPRECES is the dominant se-of viable tissue (toward the outer rim of the tumors) and neigh-
boring regions of disrupted vascular structure along with large quence of the motif, since another APA binding peptide (se-
quence CPRECESN) was effective in vitro and also yieldedareas of widespread cell death and destruction of the tumor
architecture; inhibitory peptides had similar but less pronounced therapeutic effects in vivo (data not shown). Because a search
of human databases for sequences homologous to the selectedeffect on treated tumors (Figure 7D).
Taken together, these results indicate that APA-inhibitory peptides did not yield matches consistent with potential APA
ligands, the biological substrate responsible for APA inhibitionligands can specifically target angiogenic vasculature and sup-
press tumor growth in vivo. by the consensus motif CPRECESIC may remain unknown until
the three-dimensional structure of the interaction of ligand pep-
tides and the APA active site has been solved.Discussion
To define the functional basis for the role of APA in blood
vessel formation, we used in vitro and in vivo angiogenesisSeveral approaches indicate that the vascular endothelium of
angiogenic blood vessels expresses surface markers that are assays. Because our evaluation of APA enzyme activity in freshly
isolated endothelial cells led to the observation of high enzymeaccessible from the circulation in tumors but are undetectable,
inactive, or inaccessible in normal blood vessels. Such cell activity in HMECs and in some tumor-derived endothelial cells
(our unpublished data), we used HMECs in our in vitro angiogen-markers include growth factor receptors, cell adhesion mole-
cules, proteoglycans, and proteases. Membrane-associated esis assays. We found that the synthetic CPRECESIC peptide
inhibited VEGF-induced migration and proliferation of HMECs.proteases such as gelatinases and aminopeptidases have been
found to be molecular targets in tumor blood vessels (Koivunen CPRECESIC peptide also inhibits cord/tube formation of micro-
vascular endothelial cells in a Matrigel assay and angiogenesiset al., 1999; Pasqualini et al., 2000).
Here we set out to determine the role of APA as a functional in VEGF-stimulated CAMs. These results show (1) that the con-
sensus motif CPRECESIC is an inhibitor of APA enzymatic activ-target for inhibition of angiogenesis. We predicted that genetic
elimination of APA or biochemical inhibition of its enzymatic ity and a suppressor of migration and proliferation of endothelial
cells and (2) that inhibition of APA enzymatic activity leads toactivity would lead to insights into mechanisms of abnormal
blood vessel formation. We also reasoned that identification of a dose-dependent decrease in cord/tube formation during angi-
ogenesis.a specific APA ligand might yield a desirable targeting tool,
given the high expression and activity of this protease in the APA appears to be one of the many molecules that have
been shown to play different roles, according to the organ andnewly formed blood vessels of human tumors.
Knockout APA/ mice develop normally (Lin et al., 1998), time period examined. A broad spectrum of tissues expresses
APA (Li et al., 1993), but its only well understood role is thebut our study shows a severely impaired angiogenic response
to oxygen-induced retinopathy in a mouse model of retinopathy conversion of angiotensin II to angiotensin III in the renin-angio-
tensin system (Jackson, 2001). In vivo, angiotensin II remainsof prematurity (Smith et al., 1994). They also failed, compared to
APA/ mice, to sprout new blood vessels into subcutaneously the sole characterized substrate for APA. While angiotensins
are usually investigated in relation to mechanisms of arterialimplanted angiogenic factor-containing sponges (McCarty et
al., 2002). The fact that APA/ mice develop normally with no hypertension, several studies suggest a role for angiotensins in
blood vessel formation (Le Noble et al., 1996; Monton et al.,gross phenotypic abnormalities suggests that while APA may
participate in embryonic angiogenesis, it is not an essential 1998; Nadal et al., 2002; Walsh et al., 1997). Furthermore, inhibi-
tion of angiotensin-I-converting enzyme suppresses angiogen-participant. The molecular events associated with de novo for-
mation of blood vessels (“vasculogenesis”) during early devel- esis (Volpert et al., 1996; Yoshiji et al., 2001). While APA is
strongly expressed by angiogenic microvessels (Schlingemannopment may be redundant or compensated by other proteases.
Our data indicate a functional role for APA in the formation of et al., 1996), we have confirmed that it is undetectable or barely
detectable in normal vasculature. The established involvementnew blood vessels from a preformed vascular bed (“angiogen-
esis”). These data strengthen the candidacy of APA as a specific of angiotensins in angiogenesis referenced above and the over-
expression of APA in angiogenic blood vessels suggest a mech-vascular target to inhibit abnormal angiogenesis associated with
tumor formation and retinal neovascularization. anism for APA in neovascularization. As predicted by our hy-
pothesis that APA is a functional target for molecular agentsIn addition to probing the two mouse models in APA/mice,
we screened a combinatorial peptide library to gain insights into that can inhibit angiogenesis, we observed a decreased neovas-
cularization in APA/ mice following induction of angiogenesisthe role of APA activity in angiogenesis. Given the molecular
diversity of the vasculature (St. Croix et al., 2000; Arap et al. by hypoxia and by growth factors and reduced tumor growth
in mice treated with APA inhibitors. Our data are reminiscent2002), we reasoned that this approach would yield probes to
study APA function in endothelium-derived cells, and possibly of those showing a stimulatory effect of angiotensins on endo-
thelial cell migration (Kifor and Dzau, 1987) and proliferationligands to target tumor blood vessels in vivo. We selected APA-
biding phage displaying the sequences CYNLCIRECESICGAD (Monton et al., 1998). Also, angiotensin receptors are expressed
in the CAM, suggesting that angiotensins might play a role inGACWTWCADGCSRSC, CPKVCPRECESNC, and CLGQCAS
ICVNDC. The first two phage clones bound specifically to APA angiogenesis and capillary branching (Le Noble et al., 1996).
Our results, however, could also reflect a more general effectand their binding was specifically inhibited by the cognate syn-
thetic CPRECESIC motif. Binding of the CLGQCASICVNDC of APA on angiogenic mechanisms such as a role in degradation
of extracellular matrix by processing other unknown substratesphage to APA was not inhibited by CPRECESIC peptide, possi-
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(Sang, 1998). Natural and synthetic inhibitors of other metallo- rial strategies targeting both the endothelial and perivascular
proteases inhibit not only in vivo angiogenesis (Egeblad and cell compartments are likely to provide improved efficacy for
Werb, 2002; Koivunen et al., 1999; Pasqualini et al., 2000; Sang, antiangiogenic therapies in multiple stages of tumorigenesis
1998), but also migration and proliferation of microvascular cells (Bergers et al., 2003).
in vitro (Murphy et al., 1993; Zempo et al., 1996). Also, knockout Given that the selected APA binding phage home to tumor
mice in which other metalloproteases have been eliminated vasculature, and the consensus motif deduced from APA bind-
(such as MMP-2 or -9) show a defect in angiogenesis (reviewed ing peptides specifically inhibits APA enzymatic activity, we
in Egeblad and Werb, 2002). evaluated whether APA binding peptides can be used as tar-
In addition to mouse models, we evaluated whether abnor- geted inhibitory carriers. Although APA is also expressed in
mal angiogenesis associated with certain human diseases is many cell types in normal tissues (Alliot et al., 1999; Li et al.,
related to APA in the vasculature. We examined expression and 1993), our results show that APA is exposed, active, and avail-
activity of APA in malignant gliomas and metastatic carcinomas able for binding to circulating ligands from the luminal side of the
to the brain. We showed not only that APA is present in angio- vascular endothelium because APA binding phage selectively
genic blood vessels of human malignant gliomas, but also that target tumor vasculature. Based on the phage recovery from
the protein overexpressed in the perivascular cells is enzymati- tissues and phage immunohistochemistry, we showed that the
cally active. In contrast, the presence of the enzyme and its CPKVCPRECESNC phage targets angiogenic blood vessels in
corresponding proteolytic activity were undetectable in the human breast carcinoma-derived tumor xenografts.
blood vessels and adjacent normal brain. Pericytes, which were Finally, after documenting the expression of the target in the
once seen merely as the contractile microvessel equivalent of tumor vasculature, in a mouse model of mammary carcinoma
smooth muscle cells surrounding larger blood vessels, also play (Deroanne et al., 1997, Hajitou et al., 2001), we successfully
an active role in neovascularization and maturation, remodeling, targeted this tumor with the same APA binding phage and have
and maintenance of the vascular system (Morikawa et al., 2002; chosen this model for therapy experiments. We showed that
Schlingemann et al., 1991). Similarly to endothelial cells, peri- APA-inhibitory ligands—such as the APA binding peptides de-
vascular cells also exhibit molecular, functional, and structural scribed here or anti-APA monoclonal antibodies (Assmann et
heterogeneity (Morikawa et al., 2002), of which APA overexpres- al. 1992)—specifically target angiogenic vasculature and can
sion in tumor blood vessels is one example. APA may play a suppress tumor growth in vivo in this experimental system. We
significant role in several functions of perivascular cells, such determined the IC50 of the ASD-37 monoclonal antibody for the
as secretion of growth factors, modulation of the extracellular APA enzyme activity and found it to be60 nM (data not shown).
matrix, and regulation of vascular permeability. The apparently superior inhibitory ability of anti-APA monoclonal
The overexpression of APA in activated blood vessels has antibodies is commensurate with, and one likely explanation
been associated with perivascular cells in human tumors here for, the more evident histopathological findings observed after
and elsewhere (Schlingemann et al., 1996), but the exact cellular treatment with such antibodies relative to our APA binding pep-
location of active APA in the vascular endothelium of blood tides. Considering these promising preclinical results, and the
vessels during tumorigenesis is still not entirely clear. A further fact that antibody-related toxicity occurred only when mice re-
level of complexity arises because tumor cells per se express ceived over 20-fold the doses that yielded the antitumor activity
APA in several human cancers (Fujimura et al., 2000; Geng et observed here (Assmann et al. 1992, Mentzel et al., 1999), anti-
al., 1998; Ino et al., 2000), making it difficult to differentiate the APA inhibitory antibodies should be at least considered as can-
origin of APA enzymatic activity. In this study, we show that didates for drug development and, possibly, translation into
APA expression and activity are strongly increased in tumor clinical applications.
blood vessels during late stages of human malignant glioma In sum, our results reveal a new role for APA and its targeted
progression. We have also observed that endothelial cells de-
ligands in angiogenesis. The interaction between APA and its
rived from mature macrovessels like human umbilical vein endo-
ligands has a functional role in abnormal angiogenesis. We show
thelial cells express little or no APA, while HMECs, extracted
that APA binding peptides inhibit its proteolytic activity and
from small, immature blood vessels, show much higher APA
affect endothelial cell functions and angiogenesis. The ligandexpression (unpublished data). One might speculate that this
motif described here may therefore serve as a peptidomimeticprocess mimics an angiogenic switch (Hanahan and Folkman,
drug lead against angiogenic mechanisms. Taken together, this1996) in which endothelial cells are recruited to form new capil-
study shows that APA is a specific vascular target to be criticallylaries for extensive tumor growth. Once tumor blood vessels
evaluated in translational clinical trials against pathologic angio-mature to the stage at which they are covered with perivascular
genesis.cells, APA expression is reduced in the endothelial cells. In turn,
activated perivascular cells covering more mature tumor blood
Experimental procedures
vessels express high levels of APA. Due to its specific expres-
sion and accessibility to tumor blood vessels, APA in the cell Reagents
membranes of activated endothelial cells or perivascular cells VEGF-A165, bFGF, and TGF- were from R&D Systems (Minneapolis, MN)
and anti-CD31 antibody from BD-Pharmingen (San Diego, CA). RC38can be systemically targeted, which makes it a suitable candi-
(Schlingemann et al., 1996), ASD-37, ASD-41 (Assmann et al., 1992), anddate receptor for targeted imaging or therapy. Openings be-
PAL-E antibody (Schlingemann et al., 1985) have been described. Synthetictween defective endothelial cells of tumor blood vessels (Hashi-
peptides were purchased from AnaSpec (San Jose, CA). Unless otherwise
zume et al., 2000) enable access to the perivascular cell layer indicated, an unrelated synthetic peptide (sequence GACVRLSACGA) was
of the vasculature; other cell surface receptors of activated used as a negative control. A phage display random peptide library displaying
perivascular cells (such as the proteoglycan NG2) have been the insert CX3CX3CX3C (C, cysteine; X, any amino acid residue) was con-
structed as described (Smith and Scott, 1993).targeted by in vivo phage display (Burg et al., 1999). Combinato-
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Cell culture cells in complete M199 medium. HMECs were then serially fixed in 2.5%
glutaraldehyde, stained with 0.1% crystal violet in 20% methanol, and solubi-Renal carcinoma cells SK-RC-49 (Ebert et al., 1990) were stably transfected
with a mammalian expression vector encoding the full-length APA cDNA lized in 10% acetic acid. Cell growth was evaluated by measuring ab-
sorbance at 590 nm. A calibration curve with linear correlation between(Geng et al., 1998) and HMECs stably transfected with large T (Ades et al.,
1992). EF43-fgf4 cells have been described (Deroanne et al., 1997, Hajitou absorbance and cell number (103–105 HMECs) was used for the assay.
et al., 2001).
Chemotaxic assay
Cell migration assays were performed in a 48-well Boyden chamber (Neuro-Animals
Institutional animal care and utilization committees approved animal experi- Probe; Gaithersburg, MD) as described (Bussolino et al., 1995). Indicated
concentrations of CPRECESIC peptide or negative control peptide (1 mM)ments. This study adhered to the Association for Research in Vision and
Ophthalmology (ARVO) guidelines. The APA/ strain of inbred C57BL/6 were placed in the lower chamber compartment in complete M199 medium.
Subconfluent HMECs were harvested and 1 	 105 cells were seeded in themice has been described (Lin et al., 1998). Nude mice and Balb/c mice were
obtained from Jackson Laboratory (Bar Harbor, Maine). upper chamber compartment in complete M199 medium. Cells were allowed
to migrate for 5 hr at 37C in a humidified 5% CO2 atmosphere. Filter was
removed and cells on the upper side were scraped off. Migrated cells wereMouse model of retinal neovascularization
fixed and Giemsa stained.P7 mouse pups were exposed to 75% oxygen for 5 days. Mice were returned
to room air (20.8% O2) on P12 (Smith et al., 1994). For histological analysis,
mice were sacrificed on P19, eyes were enucleated, fixed, serially sectioned, Three-dimensional cell culture
Matrigel (BD Biosciences; Bedford, MA) was added to 48-well tissue cultureand stained with hematoxylin and eosin (H&E). Endothelial cell nuclei on the
vitreous side of the internal limiting membrane were counted. At least 10 plates and allowed to solidify at 37C. HMECs (104 cells) were added to
the wells and allowed to adhere to the Matrigel for 30 min at 37C. CellH&E-stained sections were evaluated per eye, and the average number of
nuclei was counted from 4–16 eyes for each condition. medium was replaced containing the indicated concentrations of CPRECE
SIC or a negative control peptide (both at 1 mM) in complete medium. Plates
were examined and photographed after 16 hr.In vivo angiogenesis assay
We used an angiogenesis assay in which gelfoam sponges (Pharmacia &
Upjohn, Kalamazoo, MI) impregnated with VEGF, bFGF, and TGF- (200 Chick embryo chorioallantoic membrane assay
ng/ml each) are implanted in vivo as described (McCarty et al., 2002). Fertilized chicken eggs were incubated in constant humidity at 37C for 3
Sponges were implanted into the subcutaneous tissue of homozygous days. 2–3 ml of albumin was removed through a square opening to detach
APA/ or APA/ mice. After 14 days, anesthetized mice were perfused the developing CAM. The opening was sealed with a glass plate and the
with 4% paraformaldehyde (PAF). Sponges were fixed with 4% PAF, frozen, eggs were incubated for 5 days. 1 mm3 gelfoam sponges were adsorbed
and sectioned at 50 m. Sections were stained with an anti-CD31 antibody with 20 ng of VEGF, or 20 ng of VEGF plus 1 mM CPRECESIC or negative
and a Cy3-conjugated secondary antibody. Quantification of CD31 cells control peptide, and implanted on top of the growing CAMs. CAMs were
was determined (McCarty et al., 2002). examined daily until day 12, photographed in ovo with a stereomicroscope
and emerging capillaries were counted (Ribatti et al., 1997).
Cell surface panning
We preadsorbed 1010 transducing units (TU) of a CX3CX3CX3C (C, cysteine; In situ enzyme histochemistry
X, any amino acid residue) phage display random library on SK-RC-49 Biopsy materials were snap frozen and serially sectioned at 5 m. Acetone-
parental cells. Next, the precleared CX3CX3CX3C phage library (1010 TU) fixed tissue sections were incubated at 37C with 1.6 mM of the APA-specific
was added to 106 detached APA-transfected SK-RC-49 cells in binding substrate N-Glutamyl-4-methoxy-3-naphtylamide (Bachem; Bubendorf,
medium (20 mM HEPES, 2% FCS in DMEM). Cell panning was performed Switzerland) and 1.1 mM Fast Blue B salt in 0.1 M Tris (pH 7.0) containing
at 4C to minimize postbinding events such as receptor-mediated internaliza- 2.5 mM CaCl2. Tissue sections were fixed, stained with H&E, and examined
tion (Giordano et al., 2001). Cells were washed with binding medium and with a light microscope.
cell bound phage were recovered and amplified by infection of K91Kan
E. coli. Serial dilutions were plated on Luria-Bertani (LB) agar plates with Immunoperoxidase, immunofluorescence,
tetracycline and kanamycin. The number of TU was determined by bacterial and immuno-electron microscopy
colony counting. Frozen sections of colon adenocarcinoma metastases to the brain were
immunoperoxidase-stained with RC38 antibody by using diaminobenzidine
APA immunocapture and enzymatic assay (DAB) as substrate (brown staining product). Tissue sections were washed
Cells lysates were prepared in ice-cold 100 mM N-octyl-
-glucopyranoside with 0.1 M Glycine-HCL (pH 3.0) to block peroxidase activity and then stained
in PBS. Microtiter wells were coated with 2 g of RC38 and blocked with in a second round of immunoperoxidase staining with PAL-E antibody by
3% BSA. Cell lysates (1 mg of protein/ml) were incubated on RC38-coated using 4-chloro-1-naphtol as substrate (blue-gray staining product). 60 m
wells overnight at 4C. Wells were washed with 0.1% Tween-20 in PBS. The frozen sections of EF43-fgf4 tumors were double stained with ASD-37 and
assay for APA enzymatic activity with -L-glutamyl-p-nitroanilide has been anti-CD31 antibodies. ASD-37 staining was detected by Cy3-conjugated
described (Lin et al., 1998). Activity was determined by measuring ab- secondary antibody and CD31 staining was detected by FITC-conjugated
sorbance at 405 nm. secondary antibody.
Immuno-electron microscopy was performed for biopsy materials as
described by Schlingemann et al. (1996).Binding assays on APA or on APA-transfected cells
Binding assays were performed on cells with 109 TU phage input. Increasing
concentrations of synthetic CPRECESIC or control peptides were used to Tumor homing in vivo and therapy experiments
evaluate competitive inhibition of phage binding. APA was immunocaptured Nude mice bearing tumor xenografts derived from MDA-MB-435 human
on microtiter wells with RC38 and incubated with 109 TU of phage in 3% breast cancer cells were generated as described (Arap et al., 1998). 109
BSA in PBS. Wells were washed with 1% BSA, 0.01% Tween-20 in PBS, TU of CPKVCPRECSNC-displaying phage or fd-tet phage were injected
and phage were recovered by infection of K91kan E. coli. Serial dilutions intravenously to anesthetized mice. Phage were allowed to circulate for 5
were plated on LB agar plates containing tetracycline and kanamycin. The min and the animals were perfused through the left ventricle of the heart with
number of TU was determined by bacterial colony counting. DMEM. The tumor and control organs were dissected and equal amounts of
tissue were homogenized. Homogenates were washed with ice-cold DMEM
containing a protease inhibitor cocktail (Sigma; St. Louis, MO) and 0.1%Endothelial cell growth assay
HMECs were seeded (10,000 cells/well) and allowed to attach for 24 hr BSA. Tissue-bound phage were recovered as described above the cell pan-
ning. Tissue samples from the injected animals were fixed, sectioned at 5in complete M199 medium (Sigma; St. Louis, MO). The indicated concentra-
tions of CPRECESIC or 1 mM negative control peptide were added to the m, and stained with an anti-M13 antibody.
160 CANCER CELL : FEBRUARY 2004
A R T I C L E
Fujimura, H., Ino, K., Nagasaka, T., Nakashima, N., Nakazato, H., Kikkawa,For experimental therapy, Balb/c mice bearing EF43-fgf4-derived tu-
F., and Mizutani, S. (2000). Aminopeptidase A expression in cervical neopla-mors were established and tumor volumes determined as described (De-
sia and its relationship to neoplastic transformation and progression. Oncol-roanne et al., 1997; Hajitou et al., 2001). Treatments in tumor-bearing mice
ogy 58, 342–352.were started 5 (peptides) to 7 days (antibodies) after cell inoculation (105
cells/mouse). Reagents were administered by ip and sc routes. Geng, Y., Biffi, A., Engelstein, D., Ronch, E., Faustini, M., Lai, H.K., Albino,
A.P., Di Fronzo, G., and Nanus, D.M. (1998). Expression of the kidney-
Statistical analysis associated differentiation glycoprotein gp160 and resistance to the antitumor
Student’s t tests were used for statistical analysis. effects of interferon alpha in renal cell carcinomas. Anticancer Res. 18, 1–7.
Giordano, R.J., Cardo´-Vila, M., Lahdenranta, J., Pasqualini, R., and Arap,Acknowledgments
W. (2001). Biopanning and rapid analysis of selective interactive ligands.
Nat. Med. 7, 1249–1253.We thank Drs. A. Joyner and T.J. Langley for reagents and H. Sage and I.
J. Fidler for reading of the manuscript. This work was funded by grants from Hajitou, A., Sounni, N.E., Devy, L., Grignet-Debrus, C., Lewalle, J.M., Li,
NIH (CA88106, CA078512, CA90270, and CA82976 to R.P.; CA103042, H., Deroanne, C.F., Lu, H., Colige, A., Nusgens, B.V., et al. (2001). Down-
CA90270, CA90810, and DK67683 to W.A.), Juvenile Diabetes Research regulation of vascular endothelial growth factor by tissue inhibitor of metallo-
Foundation (to W.A.), Associazione Italiana per la Ricerca sul Cancro and proteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Istituto Superiore di Sanita` (to F.B.), and awards from the Gilson-Longen- Cancer Res. 61, 3450–3457.
baugh Foundation and Angelworks (to R.P. and W.A.). J.L. received fellow-
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanismsships from the Susan G. Komen Breast Cancer Foundation and the Cancer
of the angiogenic switch during tumorigenesis. Cell 86, 353–364.
Society of Finland.
Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Rob-
erge, S., Jain, R.K., and McDonald, D.M. (2000). Openings between defective
endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–
1380.Received: August 11, 2003
Revised: November 17, 2003 Ino, K., Nagasaka, T., Okamoto, T., Uehara, C., Nakazato, H., Nakashima,
Accepted: January 7, 2004 N., and Mizutani, S. (2000). Expression of aminopeptidase A in human gesta-
Published: February 23, 2004 tional choriocarcinoma cell lines and tissues. Placenta 21, 63–72.
Jackson, E.K. (2001). Renin and Angiotensin. In Goodman and Gilman’s TheReferences
Pharmacological basis of therapeutics, J.G. Hardman, L.E. Limbird, and A.
Goodman Gilman, eds. (New York: McGraw-Hill Medical Publishing Division),
Ades, E.W., Candal, F.J., Swerlick, R.A., George, V.G., Summers, S., Bosse, pp. 809–841.
D.C., and Lawley, T.J. (1992). HMEC-1: establishment of an immortalized
Kifor, I., and Dzau, V.J. (1987). Endothelial renin-angiotensin pathway: evi-human microvascular endothelial cell line. J. Invest. Dermatol. 99, 683–690.
dence for intracellular synthesis and secretion of angiotensins. Circ. Res.
Alliot, F., Rutin, J., Leenen, P.J., and Pessac, B. (1999). Pericytes and perien- 60, 422–428.
dothelial cells of brain parenchyma vessels co-express aminopeptidase N,
aminopeptidase A, and nestin. J. Neurosci. Res. 58, 367–378. Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila¨,
P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen, Y.T., et al. (1999). Tumor
Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Cancer treatment by targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768–774.
targeted drug delivery to tumor vasculature in a mouse model. Science 279,
377–380. Lahdenranta, J., Pasqualini, R., Schlingemann, R.O., Hagedorn, M., Stallcup,
W.B., Bucana, C.D., Sidman, R.L., and Arap, W. (2001). An anti-angiogenic
Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardo´-Vila, M., Gior- state in mice and humans with retinal photoreceptor cell degeneration. Proc.
dano, R.J., Mintz, P.J., Ardelt, P.U., Yao, V.J., Vidal, C.I., et al. (2002). Steps Natl. Acad. Sci. USA 98, 10368–10373.
toward mapping the human vasculature by phage display. Nat. Med. 8,
121–127. Le Noble, F.A., Kessels-van Wylick, L.C., Hacking, W.J., Slaaf, D.W., oude
Egbrink, M.G., and Struijker-Boudier, H.A. (1996). The role of angiotensin II
Assmann, K.J.M., van Son, J.P.H.F., Dijkman, H.B.P.M., and Koene, R.A.P. and prostaglandins in arcade formation in a developing microvascular net-
(1992). A nephritogenic rat monoclonal antibody to mouse aminopeptidase work. J. Vasc. Res. 33, 480–488.
A. Induction of massive albuminuria after a single intravenous injection. J.
Exp. Med. 175, 623–635. Li, L., Wu, Q., Wang, J., Bucy, R.P., and Cooper, M.D. (1993). Widespread
tissue distribution of aminopeptidase A, an evolutionarily conserved ectoen-
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. zyme recognized by the BP-1 antibody. Tissue Antigens 42, 488–496.
(2003). Benefits of targeting both pericytes and endothelial cells in the tumor
vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295. Lin, Q., Taniuchi, I., Kitamura, D., Wang, J., Kearney, J.F., Watanabe, T.,
and Cooper, M.D. (1998). T and B cell development in BP-1/6C3/aminopepti-
Burg, M.A., Pasqualini, R., Arap, W., Ruoslahti, E., and Stallcup, W.B. (1999). dase A-deficient mice. J. Immunol. 160, 4681–4687.
NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer
Res. 59, 2869–2874. McCarty, M.F., Baker, C.H., Bucana, C.D., and Fidler, I.J. (2002). Quantitative
and qualitative in vivo angiogenesis assay. Int. J. Oncol. 21, 5–10.
Bussolino, F., Arese, M., Montrucchio, G., Barra, L., Primo, L., Benelli, R.,
Sanavio, F., Aglietta, M., Ghigo, D., Rola-Pleszczynski, M.R., et al. (1995). Mentzel, S., van Son, J.P., Dijkman, H.B., Wetzels, J.F., and Assmann, K.J.
(1999). Induction of albuminuria in mice: synergistic effect of two monoclonalPlatelet activating factor produced in vitro by Kaposi’s sarcoma cells induces
and sustains in vivo angiogenesis. J. Clin. Invest. 96, 940–952. antibodies directed to different domains of aminopeptidase A. Kidney Int.
55, 1335–1347.
Deroanne, C.F., Hajitou, A., Calberg-Bacq, C.M., Nusgens, B.V., and Lapiere,
C.M. (1997). Angiogenesis by fibroblast growth factor 4 is mediated through Monton, M., Castilla, M.A., Alvarez Arroyo, M.V., Tan, D., Gonzalez-Pacheco,
F.R., Lopez Farre, A., Casado, S., and Caramelo, C. (1998). Effects of angio-an autocrine up-regulation of vascular endothelial growth factor expression.
Cancer Res. 57, 5590–5597. tensin II on endothelial cell growth: role of AT-1 and AT-2 receptors. J. Am.
Soc. Nephrol. 9, 969–974.
Ebert, T., Bander, N.H., Finstad, C.L., Ramsawak, R.D., and Old, L.J. (1990).
Establishment and characterization of human renal cancer and normal kidney Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R.K., and McDonald,
D.M. (2002). Abnormalities in pericytes on blood vessels and endothelialcell lines. Cancer Res. 50, 5531–5536.
sprouts in tumors. Am. J. Pathol. 160, 985–1000.
Egeblad, M., and Werb, Z. (2002). New functions for the matrix metallopro-
teinases in cancer progression. Nat. Rev. Cancer 2, 161–174. Murphy, A.N., Unsworth, E.J., and Stetler-Stevenson, W.G. (1993). Tissue
CANCER CELL : FEBRUARY 2004 161
A R T I C L E
inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascu- Smith, G.P., and Scott, J.K. (1993). Libraries of peptides and proteins dis-
played on filamentous phage. Methods Enzymol. 217, 228–257.lar endothelial cell proliferation. J. Cell. Physiol. 157, 351–358.
Smith, L.E., Wesolowski, E., McLellan, A., Kostyk, S.K., D’Amato, R., Sullivan,Nadal, J.A., Scicli, G.M., Carbini, L.A., and Scicli, A.G. (2002). Angiotensin
R., and D’Amore, P.A. (1994). Oxygen-induced retinopathy in the mouse.II stimulates migration of retinal microvascular pericytes: involvement of
Invest. Ophthalmol. Vis. Sci. 35, 101–111.TGF-beta and PDGF-BB. Am. J. Physiol. Heart Circ. Physiol. 282, 739–748.
St. Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgom-Nanus, D.M., Engelstein, D., Gastl, G.A., Gluck, L., Vidal, M.J., Morrison,
ery, E., Lal, A., Riggins, G.J., Lengauer, C., Vogelstein, B., and Kinzler,M., Finstad, C.L., Bander, N.H., and Albino, A.P. (1993). Molecular cloning
K.W. (2000). Genes expressed in human tumor endothelium. Science 289,of the human kidney differentiation antigen gp160: human aminopeptidase
1197–1202.A. Proc. Natl. Acad. Sci. USA 90, 7069–7073.
Volpert, O.V., Ward, W.F., Lingen, M.W., Chesler, L., Solt, D.B., Johnson,
Pasqualini, R., and Ruoslahti, E. (1996). Organ targeting in vivo using phage M.D., Molteni, A., Polverini, P.J., and Bouck, N.P. (1996). Captopril inhibits
display peptide libraries. Nature 380, 364–366. angiogenesis and slows the growth of experimental tumors in rats. J. Clin.
Invest. 98, 671–679.Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn,
A., Ashmun, R.A., Shapiro, L.H., Arap, W., and Ruoslahti, E. (2000). Amino- Walsh, D.A., Hu, D.E., Wharton, J., Catravas, J.D., Blake, D.R., and Fan, T.P.
peptidase N is a receptor for tumor-homing peptides and a target for inhib- (1997). Sequential development of angiotensin receptors and angiotensin I
converting enzyme during angiogenesis in the rat subcutaneous spongeiting angiogenesis. Cancer Res. 60, 722–727.
granuloma. Br. J. Pharmacol. 120, 1302–1311.
Ribatti, D., Gualandris, A., Bastaki, M., Vacca, A., Iurlaro, M., Roncali, L.,
Wesseling, P., Schlingemann, R.O., Rietveld, F.J., Link, M., Burger, P.C.,and Presta, M. (1997). New model for the study of angiogenesis and antiangi-
and Ruiter, D.J. (1995). Early and extensive contribution of pericytes/vascularogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/
smooth muscle cells to microvascular proliferation in glioblastoma multi-chorioallantoic membrane assay. J. Vasc. Res. 34, 455–463.
forme: an immuno-light and immuno-electron microscopic study. J. Neuro-
pathol. Exp. Neurol. 54, 304–310.Sang, Q.X. (1998). Complex role of matrix metalloproteinases in angiogen-
esis. Cell Res. 8, 171–177. Wu, Q., Lahti, J.M., Air, G.M., Burrows, P.D., and Cooper, M.D. (1990).
Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-Schlingemann, R.O., Dingjan, G.M., Emeis, J.J., Blok, J., Warnaar, S.O., and
dependent metallopeptidase family. Proc. Natl. Acad. Sci. USA 87, 993–997.Ruiter, D.J. (1985). Monoclonal antibody PAL-E specific for endothelium.
Lab. Invest. 52, 71–76. Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R.,
Nakatani, T., Tsujinoue, H., and Fukui, H. (2001). The angiotensin-I-con-
Schlingemann, R.O., Rietveld, F.J., Kwaspen, F., van de Kerkhof, P.C., de verting enzyme inhibitor perindopril suppresses tumor growth and angiogen-
Waal, R.M., and Ruiter, D.J. (1991). Differential expression of markers for esis: possible role of the vascular endothelial growth factor. Clin. Cancer
endothelial cells, pericytes, and basal lamina in the microvasculature of Res. 7, 1073–1078.
tumors and granulation tissue. Am. J. Pathol. 138, 1335–1347.
Zempo, N., Koyama, N., Kenagy, R.D., Lea, H.J., and Clowes, A.W. (1996).
Schlingemann, R.O., Oosterwijk, E., Wesseling, P., Rietveld, F.J., and Ruiter, Regulation of vascular smooth muscle cell migration and proliferation in vitro
D.J. (1996). Aminopeptidase a is a constituent of activated pericytes in and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor.
Arterioscler. Thromb. Vasc. Biol. 16, 28–33.angiogenesis. J. Pathol. 179, 436–442.
162 CANCER CELL : FEBRUARY 2004
